• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

An Update on Rosiglitazone and Cardiovascular Risk: New Meta-Analysis with Individual Patient Data

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Rosiglitazone (brand name Avandia) is an FDA-approved drug for type 2 diabetes
  • Safety issues related to CVD risk have reduced use in the US and resulted in a European ban
  • Wallach et al. (BMJ, 2019) analyzed rosiglitazone treatment and its impact on cardiovascular risk

METHODS:

  • Systematic review and meta-analysis
  • Data sources
    • GlaxoSmithKline’s (GSK’s) ClinicalStudyDataRequest.com for individual patient level data (IPD) and Study Register platforms
    • MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Registry of Controlled Trials, Scopus, and ClinicalTrials.gov from inception to January 2019
  • Study inclusion criteria
    • RCTs (phase II-IV clinical trials)
    • Minimum 24 week use in adults
  • Outcomes
    • Composite outcome (where IPD were available)
      • Acute myocardial infarction | Heart failure | Cardiovascular related death | Non-cardiovascular related death
    • Also analyzed the above events independently (secondary analyses)
    • Summary-level data analysis (where IPD not available)
      • Myocardial infarction
      • Cardiovascular related death

RESULTS:

  • 33 trials with IPD available | 21,156 patients
  • 103 trials without IPD
    • 23,683 patients included in myocardial infarction group
    • 22,772 patients included in the cardiovascular related death group

IPD data

  • IPD data: Rosiglitazone use was associated with a 33% increased risk of a composite event vs controls
    • Odds ratio (OR) 1.33 (95% CI, 1.09 to 1.61)
  • Secondary individualized outcomes
    • Myocardial infarction: OR 1.17 (95% CI, 0.92 to 1.51)
    • Heart failure: OR 1.54 (95% CI, 1.14 to 2.09)
    • Cardiovascular related death: OR 1.15 (95% CI, 0.55 to 2.41)
    • Non-cardiovascular related death: OR 1.18 (95% CI, 0.60 to 2.30)

Summary data added to IPD data

  • Risks were attenuated for the following
  • Myocardial infarction: OR 1.09 (95% CI, 0.88 to 1.35)
  • Cardiovascular related death: OR 1.12 (95% CI, 0.72 to 1.74)

CONCLUSION:

  • Results of this study indicate that rosiglitazone is associated with increased cardiovascular risk, mostly driven by heart failure and not myocardial infarction
  • Restrictions for rosiglitazone use have eased since 2013
    • Pioglitazone is preferred in the US (and is also associated with increased risk of heart failure)
  • The authors point out the importance of data transparency and that safety data may incomplete in trials

Rosiglitazone provides an ideal case to assess the impact of using IPD for safety related meta-analyses that examine relatively rare adverse events

Learn More – Primary Sources:

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Treating Type 2 Diabetes
Does Diclofenac Introduce a Disproportionate risk for Cardiovascular Disease?
Does Low-Dose Aspirin Reduce Risk of First Cardiovascular Events in Individuals at Moderate Risk?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site